ERBB2 and breast cancer: Trastuzumab is a humanized IgG1 monoclonal antibody used in epidermal growth factor receptor 2 (HER-2) positive breast cancer; its major side-effect is cardiotoxicity (reversible maternal heart failure, which resolves after its discontinuation).